Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 9/20 | 0.34 |
| ▸ | ABHD6 | Q9BV23 | 7/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553206 | 1.00 | LOXL2 (0.37) | LOXL2MGLLABHD6HCRTR2HCRTR1 | |
| SCHEMBL25324481 | 0.94 | MGLL (0.33) | LOXL2MGLLHCRTR2HCRTR1 | |
| SCHEMBL30553222 | 0.94 | MGLL (0.33) | LOXL2MGLLHCRTR2HCRTR1 | |
| SCHEMBL30553180 | 0.93 | LOXL2 (0.34) | LOXL2MGLLABHD6HCRTR2HCRTR1 | |
| SCHEMBL25327189 | 0.93 | LOXL2 (0.34) | LOXL2MGLLABHD6HCRTR2HCRTR1 | |
| SCHEMBL25326016 | 0.90 | LOXL2 (0.33) | LOXL2MGLLABHD6HCRTR2HCRTR1 | |
| SCHEMBL30553210 | 0.90 | LOXL2 (0.33) | LOXL2MGLLABHD6HCRTR2HCRTR1 | |
| SCHEMBL25325635 | 0.88 | LOXL2 (0.37) | LOXL2MGLLABHD6HCRTR2HCRTR1 | |
| SCHEMBL30553225 | 0.88 | LOXL2 (0.37) | LOXL2MGLLABHD6HCRTR2HCRTR1 | |
| SCHEMBL25326803 | 0.85 | LOXL2 (0.37) | LOXL2MGLLABHD6HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | LOXL2 3765/4885MGLL 3523/4885ABHD6 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.